Skip to main content

Table 1 Effect of huRANKL treatment of C4-2 cells on bone morphometry

From: Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases

  BV/TV (%) TuV/TV (%) Tb.Th. (μm) Tb.N. (mm-1) Tb.Sp. (μm) Ob.Pm./B.Pm. (%) N.Oc./BS (#/mm)
Control 5.88 ± 0.99 80.48 ± 2.49 31.58 ± 4.83 2.03 ± 0.42 597.24 ± 215.70 5.23 ± 1.03 4.06 ± 0.37
Prevention 6.65 ± 2.31 78.69 ± 2.06 34.27 ± 2.05 1.84 ± 0.50 690.77 ± 188.80 9.51 ± 1.76a 4.37 ± 0.71
Treatment 6.75 ± 1.72 77.85 ± 2.99 36.00 ± 4.80 1.79 ± 0.37 633.46 ± 193.00 8.35 ± 2.66 6.32 ± 0.50b
  1. Bone histomorphometric analysis was performed in the area adjacent to the growth plate (0.525–1.225 mm below the growth plate: site of injection, n = 4 in control and treatment animals; n = 5 in prevention animals. Two animals were removed from the analysis due to sectioning difficulties. Results are expressed as mean ± SE. Statistical significance was evaluated using student's paired t test. a Control vs. prevention (p < 0.05). b Control vs. treatment (p < 0.05). Abbreviations: %BV/TV, percentage bone volume in tissue volume; %TuV/TV, tumor volume in tissue volume as a percentage; Tb.Th., trabecular thickness in μm; Tb.N., trabecular number per mm; Tb.Sp., trabecular seperation in μm; Ob.Pm./B.Pm., osteoblast perimeter to bone perimeter; N.Oc./BS, ratio of osteoclast number to bone surface.